This Public Company is Going After Precision TIL
Research - Genocea is using neoantigens to develop a cancer vaccine that can add precision to TIL therapy and improve its efficacy. Iovance has validated TIL therapy. … Continue Reading
PremiumSearch Results for gene therapy
Essa Lands Janssen as mCRPC Partner After Pfizer Led Deal
Insights - Essa (EPIX) announced a collaboration with Janssen (Johnson & Johnson’s biotech arm) yesterday morning to combine EPI-7386 with their blockbuster anti-androgen drugs. Janssen will be responsible for … Continue Reading
Premium
Getting Ahead of Oncology’s Next Target With This Company
Research - Jounce is developing an ILT4 antibody that can unleash the cancer killing effect of macrophages. Combining this checkpoint inhibitor with anti-PD-1 creates a two-pronged attack … Continue Reading
Premium
Names to Watch in 2021
Insights - The prior email covered near-term 2021 catalysts for DCTH, CNCE and EPIX (HERE). The note below includes companies that we are watching with catalysts further out in 2021. Deeper dives … Continue Reading
Premium
Delcath Nearing Inflection Point With Phase 3 Data
Research - Delcath (DCTH) is developing a drug/device combination product for the treatment of liver cancer that has metastasized from other parts of the body. The initial … Continue Reading
Premium
Aducanumab ADCOM Could Lead To Spillover Effect in Other Beta-Amyloid Names
Insights - Tomorrow, Friday November 6, the FDA will hold an ADCOM for Biogen’s (BIIB) aducanumab. Aducanumab is a beta-amyloid drug for Alzheimer’s Disease that can receive … Continue Reading
Premium
ASH Abstract Shows Early AFM13 Activity As Post-Adcetris Treatment
Insights - Affimed’s (AFMD) ASH abstract for AFM13 was released today. The abstract (see here) covers AFM13 Phase 1 in relapsed/refractory CD30+ lymphoma patients. Affimed refers to this … Continue Reading
Premium